HCW Biologics Inc (HCWB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HCW Biologics Inc (HCWB) has a cash flow conversion efficiency ratio of 1.538x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.24 Million) by net assets ($-2.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HCW Biologics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how HCW Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read HCW Biologics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
HCW Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HCW Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FKS Food Sejahtera Tbk PT
JK:AISA
|
0.005x |
|
Companhia Tecidos Santanense Ltda
SA:CTSA3
|
0.074x |
|
Virax Biolabs Group Limited Ordinary Shares
NASDAQ:VRAX
|
-0.576x |
|
CREATIVEF. G.S.A-K ZY-23
F:19F
|
N/A |
|
Iofina plc
LSE:IOF
|
0.034x |
|
The Pebble Group PLC
LSE:PEBB
|
-0.019x |
|
The Real Good Food Company, Inc.
NYSE:RGFC
|
N/A |
|
STRATA Skin Sciences Inc
NASDAQ:SSKN
|
-0.049x |
Annual Cash Flow Conversion Efficiency for HCW Biologics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of HCW Biologics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see HCW Biologics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.77 Million | $-14.23 Million | 2.101x | +225.65% |
| 2023-12-31 | $13.46 Million | $-22.51 Million | -1.672x | -502.70% |
| 2022-12-31 | $37.43 Million | $-10.39 Million | -0.277x | -29.43% |
| 2021-12-31 | $51.19 Million | $-10.98 Million | -0.214x | +70.41% |
| 2020-12-31 | $14.40 Million | $-10.43 Million | -0.725x | +3.61% |
| 2019-12-31 | $9.00 Million | $-6.77 Million | -0.752x | -- |
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat p… Read more